Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
ECDC assessed the risk to the EU/EEA of the presence and the possible transmission of prions, which have been linked to Creutzfeldt-Jakob disease, by blood and plasma-derived medicinal products (PDMPs) manufactured from donations obtained in the UK.
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
This first update of the original guide was prompted by the evolution of the Zika virus epidemic, a new classification system for countries/areas, and recent scientific developments.
This document includes key elements to be considered in the risk-based decision-making process of mitigating the threats to the safety of substances of human origin posed by Zika virus.
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Following a request from the European Commission in August 2010, ECDC assessed the epidemiological history of Human T-lymphotropic Virus (HTLV) across the world, possible risks of HTLV transmission through transplantation of human tissues and cells, and possible measures to prevent such transmission.